Changes in lipid profile and glucose metabolism following administration of bupropion alone or in combination with naltrexone: A systematic review and meta‐regression analysis

Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial

(2022) Carlos M. Grilo et al.   AMERICAN JOURNAL OF PSYCHIATRY

Glucose Metabolic Dysfunction in Neurodegenerative Diseases—New Mechanistic Insights and the Potential of Hypoxia as a Prospective Therapy Targeting Metabolic Reprogramming

(2021) Rongrong Han et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

A Two-Year Follow-Up Cohort Study—Improved Clinical Control over CVD Risk Factors through Weight Loss in Middle-Aged and Older Adults

(2020) Pawel Macek et al.   Journal of Clinical Medicine

Mediterranean Diet and Naltrexone/Bupropion Treatment for Weight Loss in Overweight and Obese Breast Cancer Survivors and Non-Cancer Participants: A Pilot Randomized Controlled Trial

(2020) A-Ra Cho et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020

(2019)   DIABETES CARE

Naltrexone and Bupropion Combination Treatment for Smoking Cessation and Weight Loss in Patients With Schizophrenia

(2018) Xuechan Lyu et al.   Frontiers in Pharmacology

Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity

(2016) Amy Halseth et al.   Obesity

Diabetic dyslipidemia

(2014) Liya Wu et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Naltrexone/bupropion for obesity: An investigational combination pharmacotherapy for weight loss

(2014) Sonja K. Billes et al.   PHARMACOLOGICAL RESEARCH

Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes

(2013) P. Hollander et al.   DIABETES CARE

Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity

(2013) S. R. Smith et al.   DIABETES OBESITY & METABOLISM

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

(2013) Caroline M. Apovian et al.   Obesity

Combination therapy with naltrexone and bupropion for obesity

(2011) Sonja K Billes et al.   EXPERT OPINION ON PHARMACOTHERAPY

Adiposopathy

(2011) Harold E. Bays   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

(2010) Frank L Greenway et al.   LANCET

Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial

(2010) Thomas A. Wadden et al.   Obesity

Type 2 Diabetes Comorbidities and Treatment Challenges: Rationale for DPP-4 Inhibitors

(2010) Priscilla A. Hollander et al.   POSTGRADUATE MEDICINE

Naltrexone effects on insulin sensitivity and insulin secretion in hyperandrogenic women*

(2009) T. Sir-Petermann et al.   EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES

Comparison of Combined Bupropion and Naltrexone Therapy for Obesity with Monotherapy and Placebo

(2009) Frank L. Greenway et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Diet-induced Changes in Intra-abdominal Adipose Tissue and CVD Risk in American Women

(2009) Konstantina Katsoulis et al.   Obesity